Share to linkedin
Another driver for portfolio remodeling is the fact that companies are tiring of running major outcome studies required in some therapeutic areas for generating a successful product. For example, to justify to the medical community the importance of a new drug to lower plasma glucose, companies now need to run large outcomes studies to demonstrate that their new medicine not only lowers diabetes biomarkers but that it also reduces heart attacks and strokes.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: